Imaging Groups Oppose CMS Coverage Proposal For Beta-Amyloid PET
This article was originally published in The Gray Sheet
Executive Summary
Medical imaging manufacturers and professional societies echoed Eli Lilly’s criticism of the CMS proposal to cover beta-amyloid PET for use in patients suffering from dementia and neurodegenerative disease.